{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-26-000035","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-07-30T20:02:28+00:00","discovered_at":"2026-07-30T20:03:00.757797+00:00","generated_at":"2026-07-30T20:03:07.424863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine Q2 revenue $959M (+39% YoY); raises INGREZZA guidance to $2.825-2.875B","bullets":["GAAP EPS $1.39 vs $1.06 YoY; Non-GAAP EPS $2.85 vs $1.65 YoY.","INGREZZA net sales $716M (+15% YoY); full-year guidance raised from $2.7-2.8B to $2.825-2.875B.","CRENESSITY sales $184M (+247% YoY); VYKAT XR contributed $54M from May 18 acquisition close.","Acquired Soleno Therapeutics for $53/share ($2.9B equity value) in May; added VYKAT XR for Prader-Willi syndrome.","Entered $1.0B revolving credit facility; cash & securities $482M (down from $2.543B at year-end due to acquisition)."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-26-000035","json":"https://secwatch.observer/filing/0000914475-26-000035.json","markdown":"https://secwatch.observer/filing/0000914475-26-000035.md","text":"https://secwatch.observer/filing/0000914475-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/0000914475-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/nbix-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:03:07.424863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}